Seeking Alpha

Inovio Pharmaceuticals' (INO +14.7%) vaccine for the newly emergent A/Anhui/1/13 subtype of the...

Inovio Pharmaceuticals' (INO +14.7%) vaccine for the newly emergent A/Anhui/1/13 subtype of the H7N9 strain of bird flu protected 100% of mice in a pre-clinical study, with all the animals surviving despite receiving a lethal dose of the virus. However, Inovio is behind Novavax (NVAX), which has already started Phase I trials for A/Anhui/1/13-like A(H7N9). (PR)
Comments (2)
  • Jion
    , contributor
    Comments (540) | Send Message
     
    Inovio shareholders are expecting more important news, for HIV, in the next days.
    8 Jul 2013, 10:41 AM Reply Like
  • workhorse@bps
    , contributor
    Comments (51) | Send Message
     
    Yeah we are! Hoping for a much more substantial POP!
    8 Jul 2013, 10:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector